Facts and Figures
2016 financial year
Greiner Bio-One International GmbH strengthened its market position in all regions in the 2016 financial year. Thanks to new product solutions, expansion of production capacity and major orders, turnover increased year-on-year by 6 percent to EUR 452 million in 2016.
Greiner Bio-One again invested heavily in the further expansion of its sites and capacity, with its investment volume exceeding EUR 36 million. Production capacity was significantly increased in Brazil to meet the growing demand for blood collection tubes. Expansion of the site was completed on schedule in September 2016. In July 2016, construction work began to expand the new Greiner Bio-One headquarters in Kremsmünster. The investment volume of the project is EUR 9.3 million. In addition, new production facilities for VACUETTE® Blood Collection Tubes started operations, enabling a significant increase in output.
In line with Greiner Bio-One’s international distribution strategy, new distribution offices were opened in Milan and Istanbul in the first half of the year. The new subsidiaries in Italy and Turkey enable targeted development of those markets. Order deliveries to local customers will be even faster than before.
Greiner Bio-One continued to bring innovative products to market in the 2016 financial year. The new MiniCollect® Capillary Blood Collection System simplifies the collection of small and ultra-small volumes of blood and enables direct processing using all standard analysers. Greiner Bio-One developed the VACUETTE® FC Mix tube to inhibit the breakdown of glucose in venous blood samples (glycolysis). Use of that tube enables the stabilisation of samples for up to 48 hours. The “Greiner E-Health Technologies” business unit secured a new cooperation partner in 2016, namely Gespag (Upper Austrian healthcare and hospital groups). Innovative products have also made an impact in the BioScience segment. The CELLdisc™ cell culture device provides large growth areas in a small space and facilitates the scale-up of mass cell cultures with CryosTM Biobanking tubes, the product portfolio has been extended by a solution for high-throughput sample storage and automated storage systems.
Cash flow of EUR 63.4 million was generated in the 2016 financial year. At the end of the year, a total of 2,057 people were employed by Greiner Bio-One worldwide.
Turnover and cashflow:
2013 – 2016, figures are given in EUR millions
“The new subsidiaries bring us closer to customers and allow us to serve international markets even better.”
Rainer Perneker, CEO Greiner Bio-One International GmbH